Oncologic Drugs Advisory Committee; Cancellation

---
identifier: "/us/fr/2022-24470"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Oncologic Drugs Advisory Committee; Cancellation"
title_number: 0
title_name: "Federal Register"
section_number: "2022-24470"
section_name: "Oncologic Drugs Advisory Committee; Cancellation"
positive_law: false
currency: "2022-11-09"
last_updated: "2022-11-09"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2022-24470"
document_type: "notice"
publication_date: "2022-11-09"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "87 FR 67696"
fr_volume: 87
docket_ids:
  - "Docket No. FDA-2022-N-2174"
fr_action: "Notice."
---


#  Oncologic Drugs Advisory Committee; Cancellation

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The meeting of the Oncologic Drugs Advisory Committee scheduled for November 22, 2022, is canceled. This meeting was announced in the *Federal Register* of September 22, 2022. The meeting is no longer needed.

**FOR FURTHER INFORMATION CONTACT:**

Joyce Frimpong, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-7973, *[email protected],* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting, which was announced in the *Federal Register* of September 22, 2022 (87 FR 57904).

Dated: November 3, 2022.

Lauren K. Roth,

Associate Commissioner for Policy.